摘要
目的:探究达比加群与华法林治疗非瓣膜性房颤的临床疗效及安全性观察。方法:选取医院收治的70例非瓣膜性房颤患者,随机分为研究组(35例)和对照组(35例),研究组给予达比加群酯治疗,对照组给予华法林治疗,比较两组患者的抗凝效果及用药不良反应。结果:两组患者治疗后凝血指标均高于治疗前(P<0.01);研究组患者不良反应发生率低于对照组(P<0.05)。结论:达比加群在非瓣膜性心房颤动治疗中的应用效果显著,值得临床推广。
Objective:To explore the clinical efficacy and safety of dabigatran and warfarin in the treatment of nonvalvular atrial fibrillation.Methods:70 patients with non-valvular atrial fibrillation admitted to hospital were randomly divided into study group(35 cases)and control group(35 cases).The study group was treated with dabigatran etexilate and the control group was treated with warfarin.The anticoagulant effect and adverse drug reactions of the two groups were compared.Results:Coagulation indexes of the patients in the two groups are higher than those prior to treatment(P<0.01);and incidence of adverse reaction of research group is lower than that of the contro group(P<0.05).Conclusion:The effect of dabigatran in the treatment of nonvalvular atrial fibrillation is remarkable,which is worthy of clinical promotion.
作者
肖红刚
腊翠林
尹辉
XIAO Hong-gang;LA Cui-lin;YIN Hui(Dongguan kanghua renkang hospital,Dongguan 523000,Guangdong)
出处
《安徽卫生职业技术学院学报》
2021年第1期24-25,共2页
Journal of Anhui Health Vocational & Technical College
基金
东莞市社会科技发展(一般)项目(编号:201950715065064)。
关键词
达比加群
华法林
非瓣膜性房颤
临床疗效
安全性
dabiga group
warfarin
nonvalvular atrial fibrillation
clinical efficacy
safety
